Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMME0VN)

Drug Name
Phosphoric acid monododecyl ester Drug Info
Synonyms
Dodecyl dihydrogen phosphate; Monolauryl phosphate; Phosphoric acid, monododecyl ester; Monododecyl phosphate; 2627-35-2; Dihydrogen monolauryl phosphate; Lauryl dihydrogen phosphate; Mono-n-Dodecyl Phosphate; 12751-23-4; UNII-0K08L8GE2H; CHEMBL187711; 0K08L8GE2H; TVACALAUIQMRDF-UHFFFAOYSA-N; EINECS 220-095-4; NSC 41919; dodecylphosphoric acid; mono-Lauryl phosphate; mono-dodecyl phosphate; Momo-dodecyl phosphate; dodecyl phosphoric acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
75816
CAS Number
CAS 2627-35-2
TTD Drug ID
DMME0VN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Lysophosphatidic acid receptor 1 (LPAR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-100842 DMDMQW0 Fibrosis GA14-GC01 Phase 2 [2]
BMS-986020 DMHMV6E Scleroderma 4A42 Phase 2 [3]
BMS-986278 DMD27RW Pulmonary fibrosis CB03.4 Phase 2 [4]
BMS-986337 DM9GC6L Pulmonary fibrosis CB03.4 Phase 1 [5]
BMS-986202 DM8TAI9 Idiopathic pulmonary fibrosis CB03.4 Preclinical [6]
LPA DMI5XR1 Discovery agent N.A. Investigative [7]
Ki16425 DMJTDK9 Discovery agent N.A. Investigative [8]
dioctanoylglycerol pyrophosphate DM0QY1V Discovery agent N.A. Investigative [9]
2-oleoyl-LPA DMN9OS1 Discovery agent N.A. Investigative [10]
dodecyl-thiophosphate DMAJVPI Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysophosphatidic acid receptor 1 (LPAR1) TTQ6S1K LPAR1_HUMAN Inhibitor [1]

References

1 Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
2 Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec;8(1):e001026.
5 ClinicalTrials.gov (NCT04550195) A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety and Tolerability, and Pharmacokinetics (Including Food Effect, pH Effect and Japanese Bridging Study) of BMS-986337 Following Oral Administration in Healthy Participants. U.S.National Institutes of Health.
6 Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700.
7 Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. J Neurosci. 2010 May 26;30(21):7300-9.
8 Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol. 2012 Apr;40(4):1133-41.
9 Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001 Oct;60(4):776-84.
10 Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65.